Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses

Vaccine

Volumn 30, Issue 36, 2012, Pages 5373-5381

  Honda Okubo, Yoshikazu ^a   Saade, Fadi ^a   Petrovsky, Nikolai ^a,b  

^a VAXINE PTY LTD   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Adjuvant; Immunity; Influenza; Vaccine

Indexed keywords

ADVAX; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INFLUENZA VACCINE; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 6; INULIN; NEUTRALIZING ANTIBODY; POLYSACCHARIDE; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG POTENCY; DRUG SCREENING; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOSTIMULATION; INFLUENZA; LYMPHOCYTE PROLIFERATION; MORBIDITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN TEST;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, VIRAL; B-LYMPHOCYTES; CYTOKINES; FEMALE; INFLUENZA VACCINES; INULIN; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; T-LYMPHOCYTES;

EID: 84864000393     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.06.021     Document Type: Article

References (31)

1. Loeb M., Russell M.L., Fonseca K., Webby R., Walter S.D. Comparison of multiple estimates of efficacy for influenza vaccine. Vaccine 2011, 30(December (1)):1-4.
2. Petrovsky N., Ross T.M. Challenges in improving influenza vaccine protection in the elderly. Expert Rev Vaccines 2011, 10(January (1)):7-11.
3. Petrovsky N., Sajkov D. Pediatric influenza immunization. Expert Rev Vaccines 2011, 10(May (5)):567-570.
4. Petrovsky N., Aguilar J.C. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004, 82(October (5)):488-496.
5. Petrovsky N. Freeing vaccine adjuvants from dangerous immunological dogma. Expert Rev Vaccines 2008, 7(February (1)):7-10.
6. Cooper P.D., Petrovsky N. Delta inulin: a novel, immunologically active, stable packing structure comprising beta-d-[2→1] poly(fructo-furanosyl) alpha-d-glucose polymers. Glycobiology 2011, 21(May (5)):595-606.
7. Lobigs M., Pavy M., Hall R.A., Lobigs P., Cooper P., Komiya T., et al. An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses. J Gen Virol 2010, 91(June (Pt. 6)):1407-1417.
8. Cristillo A.D., Ferrari M.G., Hudacik L., Lewis B., Galmin L., Bowen B., et al. Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations. J Gen Virol 2011, 92(January (Pt. 1)):128-140.
9. Layton R.C., Petrovsky N., Gigliotti A.P., Pollock Z., Knight J., Donart N., et al. Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets. Vaccine 2011, 29(August (37)):6242-6251.
10. Eckersley A.M., Petrovsky N., Kinne J., Wernery R., Wernery U. Improving the dromedary antibody response: the hunt for the ideal camel adjuvant. J Camel Pract Res 2011, 18(1):35-46.
11. Ben Ahmeida E.T., Gregoriadis G., Potter C.W., Jennings R. Immunopotentiation of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice. Vaccine 1993, 11(October (13)):1302-1309.
12. Valensi J.P., Carlson J.R., Van Nest G.A. Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. J Immunol 1994, 153(November (9)):4029-4039.
13. Tan S., Gordon D.L., Honda-Okubo Y., Petrovsky N., Phillips P., Huddleston S., et al. Serological responses following influenza A H1N1 2009 infection in adults. J Infect 2011, 62(May (5)):388-393.
14. Lyons A.B. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods 2000, 243(September (1-2)):147-154.
15. Bracho G., Zayas C., Wang L., Coppel R., Perez O., Petrovsky N. AFCo1, a meningococcal B-derived cochleate adjuvant, strongly enhances antibody and T-cell immunity against Plasmodium falciparum merozoite surface protein 4 and 5. Malar J 2009, 8:35.
16. O'Hagan D.T., Wack A., Podda A. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?. Clin Pharmacol Ther 2007, 82(December (6)):740-744.
17. Grun J.L., Maurer P.H. Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses. Cell Immunol 1989, 121(June (1)):134-145.
18. Napolitani G., Rinaldi A., Bertoni F., Sallusto F., Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005, 6(August (8)):769-776.
19. Keitel W., Groth N., Lattanzi M., Praus M., Hilbert A.K., Borkowski A., et al. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. Vaccine 2010, 28(January (3)):840-848.
20. Langley J.M., Risi G., Caldwell M., Gilderman L., Berwald B., Fogarty C., et al. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J Infect Dis 2011, 203(June (12)):1729-1738.
21. Nohynek H., Jokinen J., Partinen M., Vaarala O., Kirjavainen T., Sundman J., et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One 2012, 7(3):e33536.
22. Partinen M., Saarenpaa-Heikkila O., Ilveskloski I. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 Pandemic Vaccination Campaign in Finland. PLoS One 2012, 7(3):e33723.
23. Bevan M.J. Minor H antigens introduced on H-2 different stimulating cells cross-react at the cytotoxic T cell level during in vivo priming. J Immunol 1976, 117(December (6)):2233-2238.
24. Singh-Jasuja H., Toes R.E., Spee P., Munz C., Hilf N., Schoenberger S.P., et al. Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis. J Exp Med 2000, 191(June (11)):1965-1974.
25. Webster R.G., Askonas B.A. Cross-protection and cross-reactive cytotoxic T cells induced by influenza virus vaccines in mice. Eur J Immunol 1980, 10(May (5)):396-401.
26. Tite J.P., Hughes-Jenkins C., O'Callaghan D., Dougan G., Russell S.M., Gao X.M., et al. Anti-viral immunity induced by recombinant nucleoprotein of influenza A virus. II. Protection from influenza infection and mechanism of protection. Immunology 1990, 71(Oct (2)):202-207.
27. Rimmelzwaan G.F., Fouchier R.A., Osterhaus A.D. Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr Opin Biotechnol 2007, 18(December (6)):529-536.
28. Ito S., Ishii K.J., Gursel M., Shirotra H., Ihata A., Klinman D.M. CpG oligodeoxynucleotides enhance neonatal resistance to Listeria infection. J Immunol 2005, 174(January (2)):777-782.
29. St Paul M., Mallick A.I., Read L.R., Villanueva A.I., Parvizi P., Abdul-Careem M.F., et al. Prophylactic treatment with Toll-like receptor ligands enhances host immunity to avian influenza virus in chickens. Vaccine 2012, (April).
30. Ito S., Pedras-Vasconcelos J., Klinman D.M. CpG oligodeoxynucleotides increase the susceptibility of normal mice to infection by Candida albicans. Infect Immun 2005, 73(September (9)):6154-6156.
31. Cooper P, Petrovsky N, inventors. New polymorphic form of inulin and uses thereof. Australian Patent 2004905032; 2006.